Mesoblast, which is developing regenerative medicine based on adult stem cells, raised $60 million by offering 7.5 million ADSs at $8, well below the expected $12.10 price. Mesoblast plans to list on the Nasdaq under the symbol MESO. J.P. Morgan and Credit...read more
The IPO market is having its pre-Thanksgiving feast. Nine companies are on the IPO calendar to raise a combined $1.0 billion during the week ahead. Online mortgage company loanDepot and...read more
November has kicked off with seven new additions to the IPO calendar, including four health care deals, two financial firms and one software provider. The next seven days should see...read more
US IPO Weekly Recap: IPO market turns friendly as seven companies go public
As we noted in a mid-week blog post, AAAP had the best first-day pop (+53%) for an IPO in three months, and on the same...read more
Australia-listed stem cell biotech Mesoblast prices IPO at $8, below expectations
Mesoblast, which is developing regenerative medicine based on adult stem cells, raised $60 million by offering 7.5 million ADSs at $8, well below the expected $12.10 price. Mesoblast plans to list on the Nasdaq under the symbol MESO. J.P. Morgan and Credit...read more
Week ahead: 9 IPOs set to raise $1 billion during the week of November 9
The IPO market is having its pre-Thanksgiving feast. Nine companies are on the IPO calendar to raise a combined $1.0 billion during the week ahead. Online mortgage company loanDepot and...read more
Seven deals join the November IPO calendar as market conditions improve
November has kicked off with seven new additions to the IPO calendar, including four health care deals, two financial firms and one software provider. The next seven days should see...read more